Pharmaceutical conglomerate Pfizer acquired US-based biopharmaceutical company Excaliard yesterday for an undisclosed amount yesterday in a transaction expected to close before the end of the year.
Excaliard’s only significant financing since its 2006 founding was a $15.5m series A round in November 2007, by biomedical company Isis Pharmaceuticals and venture capital firms Alta Partners, ProQuest Investments and RiverVest Venture Partners.
Pfizer will pay for the acquisition via a combination of an upfront payment with a series of milestone payments to…
